| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441419 | European Journal of Cancer | 2016 | 11 Pages |
Abstract
This long term report of the EORTC 18952 trial demonstrates the superiority of the 25-month IFN schedule and defines ulceration of the primary as the overriding predictive factor for IFN-sensitivity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alexander M.M. Eggermont, Stefan Suciu, Piotr Rutkowski, Willem H. Kruit, Cornelis J. Punt, Reinhard Dummer, François Salès, Ulrich Keilholz, Gaetan de Schaetzen, Alessandro Testori, EORTC Melanoma Group EORTC Melanoma Group,